References
- Al-Dossary OAE, Al-Shamahy HA. Oral Candida albicans colonization in dental prosthesis patients and individuals with natural teeth, Sana’a City, Yemen. Biomed J Sci Tech Res. 2018 Nov; 11(2):1-5. https://doi.org/10.26717/BJSTR.2018.11.002072
- Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM. Inactivation of sterol Δ5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother. 2005 Sept; 49(9):3646-3651. https://doi.org/10.1128/AAC.49.9.3646-3651.2005
- Clinical and Laboratory Standards Institute (CLSI). Performance standards for antifungal susceptibility testing of yeasts. 3rd ed. Wayne (PA): CLSI; 2022.
- DeJarnette C, Luna-Tapia A, Estredge LR, Palmer GE. Dihydrofolate reductase is a valid target for antifungal development in the human pathogen Candida albicans. mSphere. 2020 Jun; 5(3):e00374-20. https://doi.org/10.1128/msphere.00374-20
- Góralska K, Szybka M, Karuga FF, Pastuszak-Lewandoska D, Brzeziańska-Lasota E. Acquired resistance or tolerance? In search of mechanisms underlying changes in the resistance profile of Candida albicans and Candida parapsilosis as a result of methotrexate exposure. J Mycol Med. 2024 Jun; 34(2):101476. https://doi.org/10.1016/j.mycmed.2024.101476 PubMed+1
- Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother. 2015 Jan; 59(2):1030-1037. https://doi.org/10.1128/AAC.04613-14 PMC+1
- Hanoodi M, Mittal M. Methotrexate. In: Neuroimaging Pharmacopoeia, 2nd ed. Cham (Switzerland): Springer; 2022 Nov; p. 149161. https://doi.org/10.1007/978-3-031-08774-5 19
- Hiller D, Sanglard D, Morschhäuser J. Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob Agents Chemother. 2006 Apr; 50(4):1365-1371. https://doi.org/10.1128/AAC.50.4.1365-1371.2006
- Hirayama T, Miyazaki T, Sumiyoshi M, Ashizawa N, Takazono T, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, Kohno S, Mukae H. ERG3encoding sterol C5,6desaturase in Candida albicans is required for virulence in an enterically infected invasive candidiasis mouse model. Pathogens. 2021 Dec; 10(1):23. https://doi.org/10.3390/pathogens10010023
- Karuga FF, BrzeziańskaLasota E, Góralska K. Detection of crossresistance between methotrexate and azoles in Candida albicans and Meyerozyma guilliermondii: an in vitro study. Acta Mycol. 2021 May; 56:566. https://doi.org/10.5586/am.566 Polskie Towarzystwo Botaniczne
- Kohli A, Gupta V, Krishnamurthy S, Hasnain SE, Prasad R. Specificity of drug transport mediated by CaMDR1: a major facilitator of Candida albicans. J Biosci. 2001 Sept; 26(3):333-339. https://doi.org/10.1007/BF02703742
- Rojas AE, Cárdenas LY, García MC, Pérez JE. Expression of ERG11, ERG3, MDR1 and CDR1 genes in Candida tropicalis. Biomedica. 2023 Aug; 43(Suppl 1):144. https://doi.org/10.7705/bio-medica.6852 PubMed+1
- RuizBaca E, ArredondoSánchez RI, CorralPérez K, LópezRo-dríguez A, MenesesMorales I, AyalaGarcía VM, MartínezRocha AL. Molecular mechanisms of resistance to antifungals in Candida albicans. London (UK): IntechOpen; 2021 Mar; https://doi.org/10.5772/intechopen.96346
- Tang HJ, Liu WL, Lin HL, Lai CC. Epidemiology and prognostic factors of candidemia in cancer patients. PLoS One. 2014 Jun; 9(6):e99103. https://doi.org/10.1371/iournal.pone.0099103 PLOS+1
- Warnock DW, Johnson EM, Burke J, Pracharktam R. Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans. J Antimicrob Chemother. 1989 Jun; 23(6):837-847. https://doi.org/10.1093/jac/23.6.837
- Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhäuser J. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother. 2001 Dec; 45(12):3416-3421. https://doi.org/10.1128/AAC.45.12.3416-3421.2001
- Yang J, Gao L, Yu P, Kosgey JC, Jia L, Fang Y, et al. In vitro synergy of azole antifungals and methotrexate against Candida albicans. Life Sci. 2019 Oct; 235:116827. https://doi.org/10.1016/jJfs.2019.116827
- Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014 Feb; 10:95-105. https://doi.org/10.2147/TCRM.S40160
- Żyrek D, Nowicka J, Pajaczkowska M, Morgiel E. Does systemic methotrexate therapy induce azole resistance among endogenous Candida strains? Antibiotics (Basel). 2021 Oct; 10(11):1302. https://doi.org/10.3390/antibiotics10111302